Literature DB >> 34266597

Endocrine dysfunction in adrenoleukodystrophy.

Marc Engelen1, Stephan Kemp2, Florian Eichler3.   

Abstract

X-linked adrenoleukodystrophy (ALD) is a peroxisomal disorder caused by mutations in the ABCD1 gene and characterized by impaired very long-chain fatty acid beta-oxidation. Clinically, male patients develop adrenal failure and a progressive myelopathy in adulthood, although age of onset and rate of progression are highly variable. Additionally, 40% of male patients develop a leukodystrophy (cerebral ALD) before the age of 18 years. Women with ALD also develop a myelopathy but generally at a later age than men and with slower progression. Adrenal failure and leukodystrophy are exceedingly rare in women. Allogeneic hematopoietic cell transplantation (HCT), or more recently autologous HCT with ex vivo lentivirally transfected bone marrow, halts the leukodystrophy. Unfortunately, there is no curative treatment for the myelopathy. In the following chapter, the biochemistry, pathology, and clinical spectrum of ALD are discussed in detail.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adrenal failure; Gonadal insufficiency; Leukodystrophy; Myelopathy; Peripheral neuropathy; Peroxisomal disorders; Schilder's disease; VLCFA; Very long-chain fatty acids; X-linked adrenoleukodystrophy

Year:  2021        PMID: 34266597     DOI: 10.1016/B978-0-12-819973-2.00018-6

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  2 in total

1.  Newborn Screening for X-Linked Adrenoleukodystrophy in Nebraska: Initial Experiences and Challenges.

Authors:  Craig V Baker; Alyssa Cady Keller; Richard Lutz; Karen Eveans; Krystal Baumert; James C DiPerna; William B Rizzo
Journal:  Int J Neonatal Screen       Date:  2022-04-26

Review 2.  Monitoring for and Management of Endocrine Dysfunction in Adrenoleukodystrophy.

Authors:  Isha Kachwala; Molly O Regelmann
Journal:  Int J Neonatal Screen       Date:  2022-03-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.